Evidence map›Paper›PMID 42043868›Full record

ArticleHepatology communications2026

Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma.

Mohammad Saeid Rezaee-Zavareh, Joseph C Ahn, Hyunseok Kim, Michael Luu, Walid Ayoub, Alexander Kuo, Hirsh Trivedi, Yun Wang, Aarshi Vipani, Tsuyoshi Todo and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Mohammad Saeid Rezaee-ZavarehMiddle East Liver Diseases (MELD) Center, Tehran, Iran.
Joseph C AhnDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Hyunseok KimKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Michael LuuBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Walid AyoubKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Alexander KuoKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Hirsh TrivediKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Yun WangKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Aarshi VipaniKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Tsuyoshi TodoComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Georgios VoidonikolasComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Justin A SteggerdaComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Steven A WiselComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Todd V BrennanComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Cristina FerroneDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Irene K KimComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kambiz KosariComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nicholas NissenComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Neehar D ParikhDivision of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA.
Amit G SingalHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
Ju Dong YangKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) has a poor long-term prognosis due to high recurrence and cirrhosis-related mortality, even after potentially curative treatments such as liver transplantation (LT), surgical resection, or ablation. This study aimed to identify factors associated with ≥10-year survival in HCC patients.

methodsA retrospective cohort study was conducted among HCC patients diagnosed between 2004 and 2022 using the National Cancer Database. Multivariable Cox regression was used to identify predictors of overall survival, and logistic regression was used to identify predictors of ≥10-year survival.

resultsAmong 249,600 HCC patients, 177,585 (71.2%) died within 5 years, 8613 (3.5%) died at 5-10 years, 54,988 (22.0%) were alive with <10 years of follow-up, and 8219 (3.3%) survived ≥10 years. LT, resection, and ablation were performed in 6.6%, 9.3%, and 11% of patients, respectively. Compared with ablation as the reference group, LT [adjusted odds ratio (aOR) 11.96, 95% confidence interval (CI): 11.27-13.29] and resection (aOR: 2.83, 95% CI: 2.57-3.08) increased the odds of ≥10-year survival, while non-curative treatments reduced the odds compared with ablation (aOR: 0.50, 95% CI: 0.47-0.55). Cox regression results were consistent with the logistic model, confirming the association. Decision tree analysis confirmed LT as the dominant determinant of long-term survival. Black individuals were associated with lower odds of ≥10-year survival (aOR: 0.88, 95% CI: 0.820-0.96) and decreased likelihood of receiving LT (aOR: 0.73, 95% CI: 0.55-0.96).

conclusionsLT offers the best chance of ≥10-year survival in HCC. Ensuring equitable access is essential, especially for Black patients who have lower transplant rates and worse outcomes.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationAgedFemaleHumansMaleMiddle AgedProportional Hazards ModelsRetrospective Studiesablationliver cancerlong-term survivalNational Cancer Databasesurgical resectiontransplantation

Identifiers

PMID42043868
PMCPMC13120506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.